SCHEMBL12180551

SCHEMBL12180551

CCCCCCc1cc(C=O)sc1-c1ccc(-c2ccc(-c3sc(-c4ccc(N(c5ccccc5)c5ccccc5)cc4)cc3CCCCCC)s2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 2/20 0.52
▸ MAPT P10636 2/20 0.37
▸ LTB4R Q15722 3/20 0.34
▸ ALOX15 P16050 3/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CYSLTR2 Q9NS75 2/20 0.31
▸ CYSLTR1 Q9Y271 2/20 0.31
▸ BID P55957 3/20 0.31
▸ MCL1 Q07820 3/20 0.31
▸ BCL2L1 Q07817 2/20 0.31
▸ BAK1 Q16611 2/20 0.31
▸ KAT8 Q9H7Z6 2/20 0.31
▸ PPARG P37231 1/20 0.31
▸ PPARA Q07869 1/20 0.31
▸ EP300 Q09472 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26066513 0.89 APP (0.41) APPMAPTLTB4RALOX15CYSLTR2
SCHEMBL31030239 0.87 APP (0.45) APPCYSLTR2CYSLTR1BIDMCL1
SCHEMBL31030240 0.87 APP (0.45) APPCYSLTR2CYSLTR1BIDMCL1
SCHEMBL20625203 0.84 HIF1A (0.35) MAPTALOX15ALDH1A1CYSLTR2CYSLTR1
SCHEMBL13410123 0.84 APP (0.38) APPMAPTLTB4RALOX15CYSLTR2
SCHEMBL13410190 0.82 APP (0.39) APPMAPTLTB4RPPARA
SCHEMBL3935997 0.82 ALDH1A1 (0.38) APPMAPTLTB4RALDH1A1
SCHEMBL85799 0.81 LTB4R (0.40) MAPTLTB4RALOX15KDM4ENPC1
SCHEMBL14564003 0.81 LTB4R (0.43) APPMAPTLTB4RALDH1A1
SCHEMBL85806 0.81 LTB4R (0.41) MAPTLTB4RALOX15KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566848-A1 IMPROVED OLIGOTHIOPHENES Commonwealth Scientific and Industrial Research Organisation (AU) 2013-03-13 — — EP disclosed
US-20130042918-A1 OLIGOTHIOPHENES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARIAL ORGANISATION 2013-02-21 — — US disclosed
US-20130042918-A1 OLIGOTHIOPHENES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARIAL ORGANISATION 2013-02-21 — — US disclosed
US-20130042918-A1 OLIGOTHIOPHENES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARIAL ORGANISATION 2013-02-21 — — US disclosed
WO-2011137487-A1 IMPROVED OLIGOTHIOPHENES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130042918-A1 OLIGOTHIOPHENES NR0B2, NR2C2, NR1H2 APP 2811/4885MAPT 2747/4885LTB4R 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback